Homemarket Newsstocks News

USFDA completes first ever pre-approved inspection of Bajaj Healthcare's API facility

USFDA completes first ever pre-approved inspection of Bajaj Healthcare's API facility

USFDA completes first ever pre-approved inspection of Bajaj Healthcare's API facility
Read Time
1 Min(s) Read
Profile image

By CNBCTV18.com Nov 18, 2022 3:23:20 PM IST (Published)

Bajaj Healthcare specialises in manufacturing of Intermediates, API, formulations and Nutraceuticals.

wealth-desk wealth-desk

Buy / Sell Bajaj Health share

Recommended Articles

View All

The United States Food and Drug Administration (USFDA) has completed the pre-approval inspection of the Vadodara-based Active Pharmaceutical Ingredients (API) facility of Bajaj Healthcare Ltd. with zero observations.


This was the first-ever pre-approved inspection of the said API facility.

The US drug regulator conducted the inspection of the API facility from November 14 to November 17.

Established in 1993, Bajaj Healthcare is a leading manufacturer of APIs, intermediates, and formulations.

The company has six plants dedicated to APIs, two units for Intermediates, and one unit for formulation. BHL has a strong presence globally in countries like Europe, the US, Australia, Africa, the Middle East, and South America.

For the September quarter, the company's revenue increased by 33 percent while its net profit declined 5 percent from last year.

Shares of Bajaj Healthcare have given up most of their gains and are trading 0.6 percent higher at Rs 396.60. The stock has been flat this year, with negative returns of 3 percent.

Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!